The performance of Morgan Stanley’s MS trading business (constituting a significant portion of its top line) is expected to ...

Global equity issuance rose 20% last year, but stock market launches have so far lagged that increase, remaining far below ...

Andrew Forrest has taken a ‘bring it on’ stance in response to ExxonMobil’s defamation lawsuit, which it has filed against ...

Morgan Stanley is a buy on weakness with strong dividend growth and projected revenue growth in Q4 2024 and early 2025. Click for our MS earnings preview.

Investment banking revenues soared at Jefferies Financial in the fourth quarter, a positive sign for Wall Street as bigger banks prepare to report their results next week.

JP Morgan analyst Kian Abouhossein maintained a Neutral rating and boosted the price target from $100 to $104 on Dec. 6, 2024 ...

Morgan Stanley (MS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents ...

Wall Street giant Morgan Stanley promoted 173 of its employees to managing director roles this year, marking a 12% increase ...

Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an "overweight" rating, shifting from ...

Morgan Stanley (NYSE:MS – Get Free Report) is set to issue its quarterly earnings data before the market opens on Thursday, ...